Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 + cells

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Burba, Ilaria ^a   Colombo, Gualtiero I ^a   Staszewsky, Lidia Irene ^b   de Simone, Marco ^a   Devanna, Paolo ^a   Nanni, Simona ^c   Avitabile, Daniele ^a   Molla, Fabiola ^b   Cosentino, Simona ^a   Russo, Ilaria ^b   de Angelis, Noeleen ^b   Soldo, Annarita ^b   Biondi, Antonella ^b   Gambini, Elisa ^a   Gaetano, Carlo ^d   Farsetti, Antonella ^e   Pompilio, Giulio ^a   Latini, Roberto ^b   Capogrossi, Maurizio C ^d   Pesce, Maurizio ^a  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HISTONE DEACETYLASE; TRICHOSTATIN A; VALPROIC ACID; BIOLOGICAL MARKER; CARDIOTONIC AGENT; HISTONE DEACETYLASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD34 SELECTION; CELL DENSITY; CELL DIFFERENTIATION; CELL GROWTH; CELL RENEWAL; CELL STRUCTURE; CELL SURVIVAL; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; UMBILICAL CORD BLOOD; ACETYLATION; ANIMAL; CELL CLONE; CELL PROLIFERATION; CLUSTER ANALYSIS; CYTOLOGY; FETUS BLOOD; METABOLISM; REGENERATION; STEM CELL; WOUND HEALING;

ACETYLATION; ANIMALS; ANTIGENS, CD34; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CELL PROLIFERATION; CLONE CELLS; CLUSTER ANALYSIS; FETAL BLOOD; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICE; PHENOTYPE; REGENERATION; STEM CELLS; VALPROIC ACID; WOUND HEALING;

EID: 79960596170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022158     Document Type: Article

References (65)

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967.
2. Rossig L, Urbich C, Dimmeler S, (2004) Endothelial progenitor cells at work: not mature yet, but already stress-resistant. Arterioscler Thromb Vasc Biol 24: 1977-1979.
3. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-7.
4. Seeger FH, Zeiher AM, Dimmeler S, (2007) Cell-enhancement strategies for the treatment of ischemic heart disease. Nat Clin Pract Cardiovasc Med 4 (Suppl 1): S110-113.
5. Burba I, Devanna P, Pesce M, (2010) When cells become a drug. Endothelial progenitor cells for cardiovascular therapy: aims and reality. Recent Pat Cardiovasc Drug Discov 5: 1-10.
6. Pesce M, Burba I, Gambini E, Prandi F, Pompilio G, et al. (2011) Endothelial and cardiac progenitors: boosting, conditioning and (re)programming for cardiovascular repair. Pharmacol Ther 129: 50-61.
7. Jenuwein T, Allis CD, (2001) Translating the histone code. Science 293: 1074-1080.
8. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, et al. (2008) Dissecting direct reprogramming through integrative genomic analysis. Nature 454: 49-55.
9. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, et al. (2007) Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553-560.
10. Cui K, Zang C, Roh TY, Schones DE, Childs RW, et al. (2009) Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 4: 80-93.
11. Pesce M, Orlandi A, Iachininoto MG, Straino S, Torella AR, et al. (2003) Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res 93: e51-62.
12. Michaelis M, Doerr HW, Cinatl J Jr, (2007) Valproic acid as anti-cancer drug. Curr Pharm Des 13: 3378-3393.
13. Gerstner T, Bell N, Konig S, (2008) Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert Opin Pharmacother 9: 285-292.
14. Araki H, Mahmud N, Milhem M, Nunez R, Xu M, et al. (2006) Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol 34: 140-149.
15. Eyal S, Yagen B, Shimshoni J, Bialer M, (2005) Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol 69: 1501-1508.
16. Scharenberg CW, Harkey MA, Torok-Storb B, (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99: 507-512.
17. Povsic TJ, Zavodni KL, Kelly FL, Zhu S, Goldschmidt-Clermont PJ, et al. (2007) Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol 50: 2243-2248.
18. Ramos AL, Darabi R, Akbarloo N, Borges L, Catanese J, et al. (2010) Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood. Circ Res 107: 1460-1469.
19. Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, et al. (2009) Endothelial progenitor cells: identity defined? J Cell Mol Med 13: 87-102.
20. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, et al. (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109: 1801-1809.
21. Gianella A, Guerrini U, Tilenni M, Sironi L, Milano G, et al. (2010) Magnetic resonance imaging of human endothelial progenitors reveals opposite effects on vascular and muscle regeneration into ischaemic tissues. Cardiovasc Res 85: 503-513.
22. Gnecchi M, Zhang Z, Ni A, Dzau VJ, (2008) Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103: 1204-1219.
23. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-2984.
24. Masson S, Arosio B, Luvara G, Gagliano N, Fiordaliso F, et al. (1998) Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Mol Cell Cardiol 30: 1505-1514.
25. Whittaker P, Boughner DR, Kloner RA, (1991) Role of collagen in acute myocardial infarct expansion. Circulation 84: 2123-2134.
26. Bryant JE, Shamhart PE, Luther DJ, Olson ER, Koshy JC, et al. (2009) Cardiac myofibroblast differentiation is attenuated by alpha(3) integrin blockade: potential role in post-MI remodeling. J Mol Cell Cardiol 46: 186-192.
27. Orlandi A, Hao H, Ferlosio A, Clement S, Hirota S, et al. (2009) Alpha actin isoforms expression in human and rat adult cardiac conduction system. Differentiation 77: 360-368.
28. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, et al. (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
29. Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, et al. (2007) Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood 109: 3570-3578.
30. De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, et al. (2005) Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 65: 1505-1513.
31. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, et al. (2004) Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103: 4102-4110.
32. Seet LF, Teng E, Lai YS, Laning J, Kraus M, et al. (2009) Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions. Eur J Haematol 82: 124-132.
33. Wagner W, Ansorge A, Wirkner U, Eckstein V, Schwager C, et al. (2004) Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. Blood 104: 675-686.
34. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
35. Delorme B, Basire A, Gentile C, Sabatier F, Monsonis F, et al. (2005) Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells. Thromb Haemost 94: 1270-1279.
36. Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, et al. (2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3: 568-574.
37. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26: 1269-1275.
38. Dovey OM, Foster CT, Cowley SM, (2010) Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci U S A 107: 8242-8247.
39. Chaurasia P, Berenzon D, Hoffman R, (2011) Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood 117: 4632-4641.
40. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, et al. (2006) Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 20: 2432-2443.
41. Blank U, Karlsson G, Karlsson S, (2008) Signaling pathways governing stem-cell fate. Blood 111: 492-503.
42. Kwon SM, Alev C, Asahara T, (2009) The role of notch signaling in endothelial progenitor cell biology. Trends Cardiovasc Med 19: 170-173.
43. Scheller M, Huelsken J, Rosenbauer F, Taketo MM, Birchmeier W, et al. (2006) Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol.
44. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, et al. (2009) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69: 9038-9046.
45. Wu J, Qian J, Li C, Kwok L, Cheng F, et al. (2010) miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 9: 1809-1818.
46. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, et al. (2010) MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 176: 2520-2529.
47. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T, (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27: 378-386.
48. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, et al. (2009) Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113: 3314-3322.
49. Scarola M, Schoeftner S, Schneider C, Benetti R, (2010) miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res 70: 6925-6933.
50. Milutinovic S, D'Alessio AC, Detich N, Szyf M, (2007) Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 28: 560-571.
51. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R, (2008) miR-148 targets human DNMT3b protein coding region. Rna 14: 872-877.
52. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, et al. (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363-1372.
53. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, et al. (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
54. Rossig L, Urbich C, Bruhl T, Dernbach E, Heeschen C, et al. (2005) Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med 201: 1825-1835.
55. Spallotta F, Rosati J, Straino S, Nanni S, Grasselli A, et al. (2010) Nitric oxide determines mesodermic differentiation of mouse embryonic stem cells by activating class IIa histone deacetylases: potential therapeutic implications in a mouse model of hindlimb ischemia. Stem Cells 28: 431-442.
56. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, et al. (2007) SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 21: 2644-2658.
57. Mottet D, Bellahcene A, Pirotte S, Waltregny D, Deroanne C, et al. (2007) Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 101: 1237-1246.
58. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, et al. (2008) Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117: 3099-3108.
59. Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, et al. (2005) Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 97: 663-673.
60. Carlson S, Trial J, Soeller C, Entman ML, (2011) Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction. Cardiovasc Res.
61. Frangogiannis NG, (2008) The immune system and cardiac repair. Pharmacol Res 58: 88-111.
62. Porter KE, Turner NA, (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 255-278.
63. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, et al. (2006) Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 103: 18284-18289.
64. Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, et al. (2011) Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 50: 248-256.
65. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, et al. (2009) Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119: 1093-1108.